Strategies to prevent drug incompatibility during simultaneous multi-drug infusion in intensive care units: a literature review.
Drug incompatibility
Filtration
Infusions
Intensive care units
Intravenous
Particulate matter
Journal
European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
03
11
2020
accepted:
11
02
2021
pubmed:
27
3
2021
medline:
21
12
2021
entrez:
26
3
2021
Statut:
ppublish
Résumé
Drug protocols in intensive care units may require the concomitant administration of many drugs as patients' venous accesses are often limited. A major challenge for clinicians is to limit the risk of simultaneously infusing incompatible drugs. Incompatibilities can lead to the formation of particles and inactivation of drugs, whose consequences on the body have already been indicated. Our objective was to assess current strategies to counter the risk of incompatible infusions and control the resulting clinical consequences. This review was independently conducted by three investigators in respect of the PRISMA statement. Three online databases were consulted. Full-text articles, notes, or letters written in English or French, published or in press between the 1990s and the end of February 2020, with clinical study design, were eligible. Parameters of interest were mainly number and size of particles, and a number of observed/avoided incompatibilities. All in all, 382 articles were screened, 17 meeting all the acceptance criteria. The strategies outlined and assessed were filtration, the use of multi-lumen devices, the purging of infusion lines, incompatibility tables and databases, and the use of standard operating procedures. Although many strategies have been developed in recent years to address drug incompatibility risks, clinical data is still lacking. All studies with in vitro design were excluded although some current innovative strategies, like niosomes, should be considered and studied by means of clinical data in the future.
Identifiants
pubmed: 33768303
doi: 10.1007/s00228-021-03112-1
pii: 10.1007/s00228-021-03112-1
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1309-1321Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.
Références
Nouvel M, Lepape A (2015) Administration des médicaments par voie parentérale : incompatibilités médicamenteuses physicochimiques. Le Congrès Infirmiers Infirmier(e)s de Réanimation 2015
Langille SE (2013) Particulate matter in injectable drug products. PDA J Pharm Sci Technol 67:186–200. https://doi.org/10.5731/pdajpst.2013.00922
doi: 10.5731/pdajpst.2013.00922
pubmed: 23752747
European Pharmacopeia Commission (2020) 2.9.19 Particulate contamination: sub-visible particles. In: Pharmacopoeia, 10
The United States Pharmacopeia - National Formulary (2012) 788: particulate matters in injections. In: The United States Pharmacopoeia - USP 35-NF 30. https://www.uspnf.com/official-text/revision-bulletins/particulate-matter-injections/ . Accessed 24 August 2020
European Pharmacopeia Commission (2020) 7. Dosage forms: parenteral preparations. In: Pharmacopoeia, 10
Ilium L, Davis SS, Wilson CG, Thomas NW, Frier M, Hardy JG (1982) Blood clearance and organ deposition of intravenously administered colloidal particles. The effects of particle size, nature and shape. Int J Pharm 12:135–146. https://doi.org/10.1016/0378-5173(82)90113-2
doi: 10.1016/0378-5173(82)90113-2
Bradley JS, Wassel RT, Lee L, Nambiar S (2009) Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics 123:e609–e613. https://doi.org/10.1542/peds.2008-3080
doi: 10.1542/peds.2008-3080
pubmed: 19289450
Reedy JS, Kuhlman JE, Voytovich M (1999) Microvascular pulmonary emboli secondary to precipitated crystals in a patient receiving total parenteral nutrition: a case report and description of the high-resolution CT findings. Chest 115:892–895. https://doi.org/10.1378/chest.115.3.892
doi: 10.1378/chest.115.3.892
pubmed: 10084512
McNearney T, Bajaj C, Boyars M, Cottingham J, Haque A (2003) Total parenteral nutrition associated crystalline precipitates resulting in pulmonary artery occlusions and alveolar granulomas. Dig Dis Sci 48:1352–1354. https://doi.org/10.1023/a:1024119512162
doi: 10.1023/a:1024119512162
pubmed: 12870794
Falchuk KH, Peterson L, McNeil BJ (1985) Microparticulate-induced phlebitis. Its prevention by in-line filtration. N Engl J Med 312:78–82. https://doi.org/10.1056/NEJM198501103120203
doi: 10.1056/NEJM198501103120203
pubmed: 3880597
Knowles JB, Cusson G, Smith M, Sitrin MD (1989) Pulmonary deposition of calcium phosphate crystals as a complication of home total parenteral nutrition. JPEN J Parenter Enteral Nutr 13:209–213. https://doi.org/10.1177/0148607189013002209
doi: 10.1177/0148607189013002209
pubmed: 2496252
Jack T, Boehne M, Brent BE, Hoy L, Köditz H, Wessel A, Sasse M (2012) In-line filtration reduces severe complications and length of stay on pediatric intensive care unit: a prospective, randomized, controlled trial. Intensive Care Med 38:1008–1016. https://doi.org/10.1007/s00134-012-2539-7
doi: 10.1007/s00134-012-2539-7
pubmed: 22527062
pmcid: 3351606
Boehne M, Jack T, Köditz H, Seidemann K, Schmidt F, Abura M, Bertram H, Sasse M (2013) In-line filtration minimizes organ dysfunction: new aspects from a prospective, randomized, controlled trial. BMC Pediatr 13:21. https://doi.org/10.1186/1471-2431-13-21
doi: 10.1186/1471-2431-13-21
pubmed: 23384207
pmcid: 3571889
Sasse M, Dziuba F, Jack T, Köditz H, Kaussen T, Bertram H, Beerbaum P, Boehne M (2015) In-line filtration decreases systemic inflammatory response syndrome, renal and hematologic dysfunction in pediatric cardiac intensive care patients. Pediatr Cardiol 36:1270–1278. https://doi.org/10.1007/s00246-015-1157-x
doi: 10.1007/s00246-015-1157-x
pubmed: 25845941
pmcid: 4495711
Lehr H-A, Brunner J, Rangoonwala R, Kirkpatrick CJ (2002) Particulate matter contamination of intravenous antibiotics aggravates loss of functional capillary density in postischemic striated muscle. Am J Respir Crit Care Med 165:514–520. https://doi.org/10.1164/ajrccm.165.4.2108033
doi: 10.1164/ajrccm.165.4.2108033
pubmed: 11850345
Hill SE, Heldman LS, Goo ED, Whippo PE, Perkinson JC (1996) Fatal microvascular pulmonary emboli from precipitation of a total nutrient admixture solution. JPEN J Parenter Enteral Nutr 20:81–87. https://doi.org/10.1177/014860719602000181
doi: 10.1177/014860719602000181
pubmed: 8788269
Worthington P, Gura KM, Kraft MD, Nishikawa R, Guenter P, Sacks GS, the ASPEN PN Safety Committee (2020) Update on the use of filters for parenteral nutrition: an ASPEN position paper. Nutr Clin Pract 36:29–39. https://doi.org/10.1002/ncp.10587
doi: 10.1002/ncp.10587
pubmed: 33091206
Bethune K, Allwood M, Grainger C, Wormleighton C, British Pharmaceutical Nutrition Group Working Party (2001) Use of filters during the preparation and administration of parenteral nutrition: position paper and guidelines prepared by a British pharmaceutical nutrition group working party. Nutrition 17:403–408. https://doi.org/10.1016/s0899-9007(01)00536-6
doi: 10.1016/s0899-9007(01)00536-6
pubmed: 11377134
Mirtallo J, Canada T, Johnson D, Kumpf V, Petersen C, Sacks G, Seres D, Guenter P (2004) Safe practices for parenteral nutrition. JPEN J Parenter Enteral Nutr 28:S39–S70. https://doi.org/10.1177/0148607104028006s39
doi: 10.1177/0148607104028006s39
pubmed: 15568296
Koletzko B, Goulet O, Hunt J et al (2005) 1. Guidelines on paediatric parenteral nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), supported by the European Society of Paediatric Research (ESPR). J Pediatr Gastroenterol Nutr 41(Suppl 2):S1–S87. https://doi.org/10.1097/01.mpg.0000181841.07090.f4
doi: 10.1097/01.mpg.0000181841.07090.f4
pubmed: 16254497
Boullata JI, Gilbert K, Sacks G, Labossiere RJ, Crill C, Goday P, Kumpf VJ, Mattox TW, Plogsted S, Holcombe B, American Society for Parenteral and Enteral Nutrition, Malone A, Teitelbaum D, Andris DA, Ayers P, Baroccas A, Compher C, Ireton-Jones C, Jaksic T, Robinson LA, van Way CW III, Compher C, Allen N, Boullata JI, Braunschweig CL, George DE, Simpser E, Worthington PA (2014) A.S.P.E.N. clinical guidelines: parenteral nutrition ordering, order review, compounding, labeling, and dispensing. JPEN J Parenter Enteral Nutr 38:334–377. https://doi.org/10.1177/0148607114521833
doi: 10.1177/0148607114521833
pubmed: 24531708
P A, S A, J B, et al (2014) A.S.P.E.N. parenteral nutrition safety consensus recommendations. In: JPEN. Journal of parenteral and enteral nutrition. https://pubmed.ncbi.nlm.nih.gov/24280129/ . Accessed 11 Jan 2021
Gorski LA (2017) The 2016 infusion therapy standards of practice. Home Healthcare Now 35:10–18. https://doi.org/10.1097/NHH.0000000000000481
doi: 10.1097/NHH.0000000000000481
pubmed: 27922994
Cohen MR, Smetzer JL (2016) Selected medication safety risks to manage in 2016–part i intravenous fat emulsion needs a filter. Hosp Pharm 51:353–357. https://doi.org/10.1310/hpj5105-353
doi: 10.1310/hpj5105-353
pubmed: 27303086
pmcid: 4896341
McKinnon BT (1996) FDA safety alert: hazards of precipitation associated with parenteral nutrition. Nutr Clin Pract 11:59–65. https://doi.org/10.1177/011542659601100259
doi: 10.1177/011542659601100259
pubmed: 8788339
(1998) Safe practices for parenteral nutrition formulations. National Advisory Group on Standards and Practice Guidelines for Parenteral Nutrition. JPEN J Parenter Enteral Nutr 22:49–66
Foinard A, Décaudin B, Barthélémy C, Debaene B, Odou P (2013) The impact of multilumen infusion devices on the occurrence of known physical drug incompatibility: a controlled in vitro study. Anesth Analg 116:101–106. https://doi.org/10.1213/ANE.0b013e31826f5e02
doi: 10.1213/ANE.0b013e31826f5e02
pubmed: 23223095
Benlabed M, Perez M, Gaudy R, Genay S, Lannoy D, Barthélémy C, Odou P, Lebuffe G, Décaudin B (2019) Clinical implications of intravenous drug incompatibilities in critically ill patients. Anaesth Crit Care Pain Med 38:173–180. https://doi.org/10.1016/j.accpm.2018.04.003
doi: 10.1016/j.accpm.2018.04.003
pubmed: 29680262
Flamein F, Storme L, Maiguy-Foinard A, Perez M, Décaudin B, Masse M, Genay S, Odou P (2017) Avoid drug incompatibilities: clinical context in neonatal intensive care unit (NICU). Pharmaceut Technol Hospital Pharm 2:71–78. https://doi.org/10.1515/pthp-2017-0009
doi: 10.1515/pthp-2017-0009
Castells Lao G, Rodríguez Reyes M, Roura Turet J, Prat Dot M, Soy Muner D, López Cabezas C (2020) Compatibility of drugs administered as Y-site infusion in intensive care units: a systematic review. Med Intensiva (English Edition) 44:80–87. https://doi.org/10.1016/j.medine.2018.08.008
doi: 10.1016/j.medine.2018.08.008
Leighton H (1994) Maintaining the patency of transduced arterial and venous lines using 0.9% sodium chloride. Inten Crit Care Nurs 10:23–25. https://doi.org/10.1016/0964-3397(94)90075-2
doi: 10.1016/0964-3397(94)90075-2
LeDuc K (1997) Efficacy of normal saline solution versus heparin solution for maintaining patency of peripheral intravenous catheters in children. J Emerg Nurs 23:306–309. https://doi.org/10.1016/S0099-1767(97)90216-6
doi: 10.1016/S0099-1767(97)90216-6
pubmed: 9379571
Camut A, Noirez V, Gustin B, Khalife A (2007) Amélioration des pratiques d’administration des antibiotiques injectables : proposition et évaluation d’un guide de compatibilité physico-chimique. J Pharm Clin 26:143–150. https://doi.org/10.1684/jpc.2007.0059
doi: 10.1684/jpc.2007.0059
Bertsche T, Mayer Y, Stahl R, Hoppe-Tichy T, Encke J, Haefeli WE (2008) Prevention of intravenous drug incompatibilities in an intensive care unit. Am J Health Syst Pharm 65:1834–1840. https://doi.org/10.2146/ajhp070633
doi: 10.2146/ajhp070633
pubmed: 18796425
Nemec K, Kopelent-Frank H, Greif R (2008) Standardization of infusion solutions to reduce the risk of incompatibility. Am J Health Syst Pharm 65:1648–1654. https://doi.org/10.2146/ajhp070471
doi: 10.2146/ajhp070471
pubmed: 18714112
Bertsche T, Münk L, Mayer Y, Stahl R, Hoppe-Tichy T, Encke J et al (2009) One-year follow-up on procedure to prevent i.v. drug incompatibilities in an intensive care unit. Am J Health Syst Pharm 66:1250–1253. https://doi.org/10.2146/ajhp090070
doi: 10.2146/ajhp090070
pubmed: 19574594
Bertsche T, Veith C, Stahl A, Hoppe-Tichy T, Meyer FJ, Katus HA, Haefeli WE (2010) A purging procedure for pantoprazole and 4-lumen catheters to prevent IV drug incompatibilities. Pharm World Sci 32:663–669. https://doi.org/10.1007/s11096-010-9422-9
doi: 10.1007/s11096-010-9422-9
pubmed: 20694515
De Giorgi I, Guignard B, Fonzo-Christe C, Bonnabry P (2010) Evaluation of tools to prevent drug incompatibilities in paediatric and neonatal intensive care units. Pharm World Sci 32:520–529. https://doi.org/10.1007/s11096-010-9403-z
doi: 10.1007/s11096-010-9403-z
pubmed: 20556656
Isemann B, Sorrels R, Akinbi H (2012) Effect of heparin and other factors associated with complications of peripherally inserted central venous catheters in neonates. J Perinatol 32:856–860. https://doi.org/10.1038/jp.2011.205
doi: 10.1038/jp.2011.205
pubmed: 22301530
Häni C, Vonbach P, Fonzo-Christe C, Russmann S, Cannizzaro V, Niedrig DF (2019) Evaluation of incompatible coadministration of continuous intravenous infusions in a pediatric/neonatal intensive care unit. J Pediatr Pharmacol Therapeutics 24:479–488. https://doi.org/10.5863/1551-6776-24.6.479
doi: 10.5863/1551-6776-24.6.479
van Lingen RA, Baerts W, Marquering ACM, Ruijs GJHM (2004) The use of in-line intravenous filters in sick newborn infants. Acta Paediatr 93:658–662. https://doi.org/10.1111/j.1651-2227.2004.tb02993.x
doi: 10.1111/j.1651-2227.2004.tb02993.x
pubmed: 15174791
van den Hoogen A, Krediet TG, Uiterwaal CSPM, Bolenius JFGA, Gerards LJ, Fleer A (2006) In-line filters in central venous catheters in a neonatal intensive care unit. J Perinat Med 34:71–74. https://doi.org/10.1515/JPM.2006.009
doi: 10.1515/JPM.2006.009
pubmed: 16489888
Jack T, Brent BE, Boehne M, Müller M, Sewald K, Braun A, Wessel A, Sasse M (2010) Analysis of particulate contaminations of infusion solutions in a pediatric intensive care unit. Intensive Care Med 36:707–711. https://doi.org/10.1007/s00134-010-1775-y
doi: 10.1007/s00134-010-1775-y
pubmed: 20165942
pmcid: 2837187
Gradwohl-Matis I, Brunauer A, Dankl D, Wirthel E, Meburger I, Bayer A, Mandl M, Dünser MW, Grander W (2015) Influence of in-line microfilters on systemic inflammation in adult critically ill patients: a prospective, randomized, controlled open-label trial. Ann Intensive Care 5:36. https://doi.org/10.1186/s13613-015-0080-x
doi: 10.1186/s13613-015-0080-x
pubmed: 26538309
pmcid: 4633471
Schmitt E, Meybohm P, Herrmann E, Ammersbach K, Endres R, Lindau S, Helmer P, Zacharowski K, Neb H (2019) In-line filtration of intravenous infusion may reduce organ dysfunction of adult critical patients. Crit Care 23:373. https://doi.org/10.1186/s13054-019-2618-z
doi: 10.1186/s13054-019-2618-z
pubmed: 31757216
pmcid: 6874814
Handbook on Injectable Drugs (2018). 20th ed. ASHP
IBM Micromedex (2020). https://www.micromedexsolutions.com/home/dispatch . Accessed 24 August 2020
CNHIM. Thériaque (2020). http://www.theriaque.org/apps/contenu/accueil.php/; 2020. Accessed 24 August 2020
Stabilis 4.0. https://www.stabilis.org/; 2020. Accessed 24 August 2020
Maison O, Tardy C, Cabelguenne D, Parat S, Ducastelle S, Piriou V, Lepape A, Lalande L (2019) Drug incompatibilities in intravenous therapy: evaluation and proposition of preventive tools in intensive care and hematology units. Eur J Clin Pharmacol 75:179–187. https://doi.org/10.1007/s00228-018-2602-6
doi: 10.1007/s00228-018-2602-6
pubmed: 30543036
Sicard G, Venton G, Farnault L, Costello R, Fanciullino R, Gensollen S (2019) Mise en place d’un outil d’aide à la détection des interactions physico-chimiques en Y des médicaments injectables : analyse rétrospective des prescriptions dans un service d’hématologie. Le Pharmacien Hospitalier et Clinicien 54:348–355. https://doi.org/10.1016/j.phclin.2019.06.002
doi: 10.1016/j.phclin.2019.06.002
Manrique-Rodríguez S, Sánchez-Galindo A, Mora-García T, Fernandez-Llamazares CM, Echarri-Martínez L, López-Herce J, Rodríguez-Gómez M, Bellón-Cano JM, Sanjuro-Sáez M (2012) Development of a compatibility chart for intravenous Y-site drug administration in a pediatric intensive care unit. J Infus Nurs 35:109–114. https://doi.org/10.1097/NAN.0b013e3182425b34
doi: 10.1097/NAN.0b013e3182425b34
pubmed: 22382795
Vijayakumar A, Sharon EV, Teena J, Nobil S, Nazeer I (2014) A clinical study on drug-related problems associated with intravenous drug administration. J Basic Clin Pharm 5:49–53. https://doi.org/10.4103/0976-0105.134984
doi: 10.4103/0976-0105.134984
pubmed: 25031500
pmcid: 4074696
Bourhis M, Tortolano L, Lalioui S, Chardonnet F, Dufour C, Gaudin A, Valteau-Couanet D, Lemare F (2017) Évaluation et optimisation des pratiques de perfusion en oncologie pédiatrique. Le Pharmacien Hospitalier et Clinicien 52:355–360. https://doi.org/10.1016/j.phclin.2017.05.003
doi: 10.1016/j.phclin.2017.05.003
Huddleston J, Hay L, Everett JA (2000) Patient-specific compatibility tables for the pediatric intensive care unit. Am J Health Syst Pharm 57:2284–2285. https://doi.org/10.1093/ajhp/57.24.2284
doi: 10.1093/ajhp/57.24.2284
pubmed: 11146974
Neininger MP, Buchholz P, Kiess W, Siekmeyer M, Bertsche A, Bertsche T (2018) Incompatibilities in paediatric intensive care - pitfalls in drug information. info: https://doi.org/10.1691/ph.2018.8585
Suzuki S, Mochizuki N, Iwamoto AI, Yoshida M, Murakami A, Ikegawa K, Yamaguchi M, Vigneron J (2018) Comparative evaluation of a website for drug incompatibility: Stabilis, Trissel’s Handbook and the currently available tools in Japan. Eur J Oncol Pharma 1:e0001. https://doi.org/10.1097/OP9.0000000000000001
doi: 10.1097/OP9.0000000000000001
Trissel LA (1996) Everything in a compatibility study is important. Am J Health Syst Pharm 53:2990–2990. https://doi.org/10.1093/ajhp/53.24.2990
doi: 10.1093/ajhp/53.24.2990
pubmed: 8974165
Li J, Xu M, Dong H, Zhang Z, Kang Y (2012) Drug incompatibility checking system on mobile platform. 2012 IEEE International Conference on Information and Automation, p. 568–71. https://doi.org/10.1109/ICInfA.2012.6246877
Collins JL, Lutz RJ (1991) In vitro study of simultaneous infusion of incompatible drugs in multilumen catheters. Heart Lung 20:271–277
pubmed: 1903369
Perez M, Décaudin B, Foinard A, Barthélémy C, Debaene B, Lebuffe G, Odou P (2015) Compatibility of medications during multi-infusion therapy: a controlled in vitro study on a multilumen infusion device. Anaesth Crit Care Pain Med 34:83–88. https://doi.org/10.1016/j.accpm.2014.06.003
doi: 10.1016/j.accpm.2014.06.003
pubmed: 25858619
Perez M, Décaudin B, Abou Chahla W, Nelken B, Barthélémy C, Lebuffe G, Odou P (2015) In vitro analysis of overall particulate contamination exposure during multidrug IV therapy: impact of infusion sets. Pediatr Blood Cancer 62:1042–1047. https://doi.org/10.1002/pbc.25442
doi: 10.1002/pbc.25442
pubmed: 25755136
Foinard A, Décaudin B, Barthélémy C, Debaene B, Odou P (2013) Prevention of drug delivery disturbances during continuous intravenous infusion: an in vitro study on a new multi-lumen infusion access device. Ann Fr Anesth Reanim 32:e107–e112. https://doi.org/10.1016/j.annfar.2013.06.017
doi: 10.1016/j.annfar.2013.06.017
pubmed: 23958179
Décaudin B, Dewulf S, Lannoy D, Simon N, Secq A, Barthélémy C, Debaene B, Odou P (2009) Impact of multiaccess infusion devices on in vitro drug delivery during multi-infusion therapy. Anesth Analg 109:1147–1155. https://doi.org/10.1213/ane.0b013e3181ae06e3
doi: 10.1213/ane.0b013e3181ae06e3
pubmed: 19762742
Templeton A, Schlegel M, Fleisch F, Rettenmund G, Schöbi B, Henz S, Eich G (2008) Multilumen central venous catheters increase risk for catheter-related bloodstream infection: prospective surveillance study. Infection 36:322–327. https://doi.org/10.1007/s15010-008-7314-x
doi: 10.1007/s15010-008-7314-x
pubmed: 18663408
Dezfulian C, Lavelle J, Nallamothu BK, Kaufman SR, Saint S (2003) Rates of infection for single-lumen versus multilumen central venous catheters: a meta-analysis. Crit Care Med 31:2385–2390. https://doi.org/10.1097/01.CCM.0000084843.31852.01
doi: 10.1097/01.CCM.0000084843.31852.01
pubmed: 14501971
Bruning EJ (1955) Pathogenesis and significance of intra-arterial foreign body embolisms of the lung in children. Virchows Arch Pathol Anat Physiol Klin Med 327:460–479. https://doi.org/10.1007/BF00955940
doi: 10.1007/BF00955940
pubmed: 13299666
Garvan JM, Gunner BW (1964) The harmful effects of particles in intravenous fluids. Med J Aust 2:1–6
doi: 10.5694/j.1326-5377.1964.tb114892.x
Comité Technique national des Infections Nosocomiales (1999) 100 recommandations pour la surveillance et la prévention des infections nosocomiales 1999
Ball PA (2003) Intravenous in-line filters: filtering the evidence. Curr Opin Clin Nutr Metab Care 6:319–325. https://doi.org/10.1097/01.mco.0000068969.34812.5d
doi: 10.1097/01.mco.0000068969.34812.5d
pubmed: 12690266
Foster J, Richards R, Showell M (2006) Intravenous in-line filters for preventing morbidity and mortality in neonates. Cochrane Database Syst Rev 2006:CD005248. https://doi.org/10.1002/14651858.CD005248.pub2
doi: 10.1002/14651858.CD005248.pub2
Virlouvet A-L, Pansiot J, Toumazi A, Colella M, Capewell A, Guerriero E, Storme T, Rioualen S, Bourmaud A, Biran V, Baud O (2020) In-line filtration in very preterm neonates: a randomized controlled trial. Sci Rep 10:5003. https://doi.org/10.1038/s41598-020-61815-4
doi: 10.1038/s41598-020-61815-4
pubmed: 32193413
pmcid: 7081338
Hellinger A, Piotrowski J, Konerding MA, Burchard W, Doetsch N, Peitgen K, Erhard J, Reidemeister J (1997) Impact of particulate contamination in crystalloid cardioplegic solutions: studies by scanning and transmission electron microscopy. Thorac Cardiovasc Surg 45:20–26. https://doi.org/10.1055/s-2007-1013678
doi: 10.1055/s-2007-1013678
pubmed: 9089970
Munsch C, Rosenfeldt F, Chang V, Newman M, Davis B (1991) Absence of particle-induced coronary vasoconstriction during cardioplegic infusion: is it desirable to use a microfilter in the infusion line? J Thorac Cardiovasc Surg 101:473–480
doi: 10.1016/S0022-5223(19)36730-3
Perez M, Décaudin B, Chahla WA, Nelken B, Storme L, Masse M et al (2018) Effectiveness of in-line filters to completely remove particulate contamination during a pediatric multidrug infusion protocol. Sci Rep 8:1–8. https://doi.org/10.1038/s41598-018-25602-6
doi: 10.1038/s41598-018-25602-6
Kuramoto K, Shoji T, Nakagawa Y (2006) Usefulness of the final filter of the IV infusion set in intravenous administration of drugs--contamination of injection preparations by insoluble microparticles and its causes. Yakugaku Zasshi 126:289–295. https://doi.org/10.1248/yakushi.126.289
doi: 10.1248/yakushi.126.289
pubmed: 16596019
Robinson LA, Braimbridge MV, Hearse DJ (1984) The potential hazard of particulate contamination of cardioplegic solutions. J Thorac Cardiovasc Surg 87:48–58
doi: 10.1016/S0022-5223(19)37442-2
Mass B, Huber C, Krämer I (1996) Plasticizer extraction of Taxol infusion solution from various infusion devices. Pharm World Sci 18:78–82. https://doi.org/10.1007/BF00579710
doi: 10.1007/BF00579710
pubmed: 8739262
Masse M, Genay S, Martin Mena A, Carta N, Lannoy D, Barthélémy C, Décaudin B, Odou P (2020) Evaluation of the stability of vancomycin solutions at concentrations used in clinical services. Eur J Hosp Pharm 27:e87–e92. https://doi.org/10.1136/ejhpharm-2019-002076
doi: 10.1136/ejhpharm-2019-002076
pubmed: 32296513
pmcid: 7147549
Pardeshi NN, Qi W, Dahl K, Caplan L, Carpenter JF (2017) Microparticles and nanoparticles delivered in intravenous saline and in an intravenous solution of a therapeutic antibody product. J Pharm Sci 106:511–520. https://doi.org/10.1016/j.xphs.2016.09.028
doi: 10.1016/j.xphs.2016.09.028
pubmed: 27832839
Hirakawa M, Makino K, Nakashima K, Kataoka Y, Oishi R (1999) Evaluation of the in-line filters for the intravenous infusion of amphotericin B fluid. J Clin Pharm Ther 24:387–392. https://doi.org/10.1046/j.1365-2710.1999.00242.x
doi: 10.1046/j.1365-2710.1999.00242.x
pubmed: 10583703
Brotschi B, Grass B, Weiss M, Doell C, Bernet V (2012) In-line filter included into the syringe infusion pump assembly reduces flow irregularities. Intensive Care Med 38:518–522. https://doi.org/10.1007/s00134-011-2452-5
doi: 10.1007/s00134-011-2452-5
pubmed: 22237747
Brent BE, Jack T, Sasse M (2007) In-line filtration of intravenous fluids retains ’spearhead’-shaped particles from the vascular system after open-heart surgery. Eur Heart J 28:1192–1192. https://doi.org/10.1093/eurheartj/ehl398
doi: 10.1093/eurheartj/ehl398
pubmed: 17142254
Foinard A, Décaudin B, Barthélémy C, Debaene B, Odou P (2012) Impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility. Ann Intensive Care 2:28. https://doi.org/10.1186/2110-5820-2-28
doi: 10.1186/2110-5820-2-28
pubmed: 22794308
pmcid: 3407719
Gasch J, Leopold CS, Knoth H (2011) Drug retention by inline filters – effect of positively charged polyethersulfone filter membranes on drug solutions with low concentration. Eur J Pharm Sci 44:49–56. https://doi.org/10.1016/j.ejps.2011.06.004
doi: 10.1016/j.ejps.2011.06.004
pubmed: 21704705
Böhrer H, Zhang CH, Krier C (1991) Decrease in the concentration of tobramycin, vancomycin and phenobarbital in administration with infusion filter. Infusionstherapie 18:96–100
pubmed: 1856006
Huber RC, Riffkin C (1975) In line final filters for removing particles from amphotericin B infusions. Am J Hosp Pharm 32:173–176
pubmed: 237416
De Muynck C, Colardyn F, Remon JP (1990) The sorption of isosorbide-5-mononitrate to intravenous delivery systems. J Pharm Pharmacol 42:433–434. https://doi.org/10.1111/j.2042-7158.1990.tb06585.x
doi: 10.1111/j.2042-7158.1990.tb06585.x
pubmed: 1979625
Sendo T, Adachi K, Otsubo K, Aoyama T, Oishi R (1996) In-line filter occlusion during intravenous delivery of injectable menatetrenone (vitamin K2). J Clin Pharm Ther 21:9–13. https://doi.org/10.1046/j.1365-2710.1996.88875888.x
doi: 10.1046/j.1365-2710.1996.88875888.x
pubmed: 8737177
Meyer K, Santarossa M, Danziger LH, Wenzler E (2017) Compatibility of ceftazidime-avibactam, ceftolozane-tazobactam, and piperacillin-tazobactam with vancomycin in dextrose 5% in water. Hosp Pharm 52:221–228. https://doi.org/10.1310/hpj5203-221
doi: 10.1310/hpj5203-221
pubmed: 28439137
pmcid: 5396990
Vogel Kahmann I, Bürki R, Denzler U, Höfler A, Schmid B, Splisgardt H (2003) Incompatibility reactions in the intensive care unit. [Five years after the implementation of a simple “colour code system”]. Anaesthesist 52:409–412. https://doi.org/10.1007/s00101-003-0481-3
doi: 10.1007/s00101-003-0481-3
pubmed: 12750824
Mohamed HB, El-Shanawany SM, Hamad MA, Elsabahy M (2017) Niosomes: a strategy toward prevention of clinically significant drug incompatibilities. Sci Rep 7:1–14. https://doi.org/10.1038/s41598-017-06955-w
doi: 10.1038/s41598-017-06955-w
Nanomedicine: a new paradigm to overcome drug incompatibilities - Abdelkader - 2020 - Journal of Pharmacy and Pharmacology - Wiley Online Library. https://onlinelibrary.wiley.com/doi/full/10.1111/jphp.13292 . Accessed 11 Jan 2021
Gwee A, Cranswick N, McMullan B, Perkins E, Bolisetty S, Gardiner K, Daley A, Ward M, Chiletti R, Donath S, Hunt R, Curtis N (2019) Continuous versus intermittent vancomycin infusions in infants: a randomized controlled trial. Pediatrics 143:143. https://doi.org/10.1542/peds.2018-2179
doi: 10.1542/peds.2018-2179
Ma NH, Walker SAN, Elligsen M, Kiss A, Palmay L, Ho G, Powis J, Bansal V, Leis JA (2020) Retrospective multicentre matched cohort study comparing safety and efficacy outcomes of intermittent-infusion versus continuous-infusion vancomycin. J Antimicrob Chemother 75:1038–1046. https://doi.org/10.1093/jac/dkz531
doi: 10.1093/jac/dkz531
pubmed: 31919504
Doesburg F, Oelen R, Renes MH, Bult W, Touw DJ, Nijsten MW (2020) Towards more efficient use of intravenous lumens in multi-infusion settings: development and evaluation of a multiplex infusion scheduling algorithm. BMC Med Inform Decis Mak 20:206. https://doi.org/10.1186/s12911-020-01231-w
doi: 10.1186/s12911-020-01231-w
pubmed: 32878609
pmcid: 7466776